Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry

Analytical Biochemistry

Volumn 427, Issue 1, 2012, Pages 52-59

  Gagez, Anne Laure ^a,b   Rouguieg Malki, Koukeb ^a,b   Sauvage, François Ludovic ^a,c   Marquet, Pierre ^a,b,c   Picard, Nicolas ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Drug metabolism; Liquid chromatography; Microsomes; Tandem mass spectrometry; UDP glucuronosyltransferase

Indexed keywords

LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PROBES;

CHENODEOXYCHOLIC ACID; DRUG METABOLISMS; GENETIC POLYMORPHISMS; HUMAN LIVER MICROSOMES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MICROSOMES; TANDEM MASS SPECTROMETRY; UDP GLUCURONOSYLTRANSFERASE;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

CHENODEOXYCHOLIC ACID; ETOPOSIDE; GLUCURONOSYLTRANSFERASE; MEFENAMIC ACID; SEROTONIN; TRIFLUOPERAZINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 84861657897     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2012.04.031     Document Type: Article

References (41)

1. C. Guillemette, E. Levesque, M. Harvey, J. Bellemare, and V. Menard UGT genomic diversity: beyond gene duplication Drug Metab. Rev. 42 2010 24 44
2. P. Lazarus, A.S. Blevins-Primeau, Y. Zheng, and D. Sun Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen Ann. NY Acad. Sci. 1155 2009 99 111
3. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, M. Takamiya, Y. Aoki, S. Ikushiro, T. Sakaki, and T. Yokoi Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers Drug Metab. Dispos. 37 2009 1759 1768
4. C.P. Strassburg, A. Strassburg, N. Nguyen, Q. Li, M.P. Manns, and R.H. Tukey Regulation and function of family 1 and family 2 UDP- glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus Biochem. J. 338 1999 489 498
5. V. Uchaipichat, P.I. Mackenzie, D.J. Elliot, and J.O. Miners Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases Drug Metab. Dispos. 34 2006 449 456
6. M.H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J.A. Williams Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction Mol. Pharmacol. 74 2008 744 754
7. R.H. Tukey, and C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu. Rev. Pharmacol. Toxicol. 40 2000 581 616
8. B. Frances, R. Gout, B. Monsarrat, J. Cros, and J.M. Zajac Further evidence that morphine-6-β-glucuronide is a more potent opioid agonist than morphine J. Pharmacol. Exp. Ther. 262 1992 25 31
9. G.S. Walker, J. Atherton, J. Bauman, C. Kohl, W. Lam, M. Reily, Z. Lou, and A. Mutlib Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy Chem. Res. Toxicol. 20 2007 876 886
10. M.H. Court Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system Drug Metab. Rev. 42 2010 209 224
11. M.H. Court Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases Methods Enzymol. 400 2005 104 116
12. R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities Drug Metab. Dispos. 35 2007 1781 1787
13. H.X. Liu, Y.Q. He, Y. Hu, Y. Liu, J.W. Zhang, W. Li, Z.T. Wang, and L. Yang Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection J. Chromatogr. B 870 2008 84 90
14. V. Uchaipichat, P.I. Mackenzie, X.H. Guo, D. Gardner-Stephen, A. Galetin, J.B. Houston, and J.O. Miners Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid Drug Metab. Dispos. 32 2004 413 423
15. M.T. Donato, S. Montero, J.V. Castell, M.J. Gomez-Lechon, and A. Lahoz Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies Anal. Bioanal. Chem. 396 2010 2251 2263
16. K. Rouguieg, N. Picard, F.L. Sauvage, J.M. Gaulier, and P. Marquet Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes Drug Metab. Dispos. 38 2010 40 45
17. N. Picard, T. Cresteil, A. Premaud, and P. Marquet Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5 Ther. Drug Monit. 26 2004 600 608
18. Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1 Drug Metab. Dispos. 31 2003 589 595
19. J. Trottier, M. Verreault, S. Grepper, D. Monte, J. Belanger, J. Kaeding, P. Caron, T.T. Inaba, and O. Barbier Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver Hepatology 44 2006 1158 1170
20. O. Barbier, D. Turgeon, C. Girard, M.D. Green, T.R. Tephly, D.W. Hum, and A. Belanger 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7) Drug Metab. Dispos. 28 2000 497 502
21. S. Krishnaswamy, S.X. Duan, L.L. Von Moltke, D.J. Greenblatt, and M.H. Court Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6 Drug Metab. Dispos. 31 2003 133 139
22. N. Picard, D. Ratanasavanh, A. Premaud, Y. Le Meur, and P. Marquet Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab. Dispos. 33 2005 139 146
23. M.A. Wynalda, K.M. Wynalda, B.M. Amore, P.E. Fagerness, and L.C. Wienkers Characterization of bropirimine O-glucuronidation in human liver microsomes Xenobiotica 33 2003 999 1011
24. M. Beaulieu, E. Levesque, D.W. Hum, and A. Belanger Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids J. Biol. Chem. 271 1996 22855 22862
25. J.O. Miners, K.M. Knights, J.B. Houston, and P.I. Mackenzie In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises Biochem. Pharmacol. 71 2006 1531 1539
26. X. He, L.M. Hesse, S. Hazarika, G. Masse, J.S. Harmatz, D.J. Greenblatt, and M.H. Court Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion Br. J. Clin. Pharmacol. 68 2009 721 730
27. M.H. Court, S. Krishnaswamy, Q. Hao, S.X. Duan, C.J. Patten, L.L. Von Moltke, and D.J. Greenblatt Evaluation of 3′-azido-3′- deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B72 polymorphism Drug Metab. Dispos. 31 2003 1125 1133
28. V. Uchaipichat, L.K. Winner, P.I. Mackenzie, D.J. Elliot, J.A. Williams, and J.O. Miners Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation Br. J. Clin. Pharmacol. 61 2006 427 439
29. P. Gaganis, J.O. Miners, and K.M. Knights Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7 Biochem. Pharmacol. 73 2007 1683 1691
30. E.A. Dierks, K.R. Stams, H.K. Lim, G. Cornelius, H. Zhang, and S.E. Ball A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry Drug Metab. Dispos. 29 2001 23 29
31. V. Dixit, N. Hariparsad, P. Desai, and J.D. Unadkat In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities Biopharm. Drug Dispos. 28 2007 257 262
32. M.T. Donato, N. Jimenez, J.V. Castell, and M.J. Gomez-Lechon Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes Drug Metab. Dispos. 32 2004 699 706
33. J.A. Williams, B.J. Ring, V.E. Cantrell, K. Campanale, D.R. Jones, S.D. Hall, and S.A. Wrighton Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes Drug Metab. Dispos. 30 2002 1266 1273
34. E. Pfeiffer, C.R. Treiling, S.I. Hoehle, and M. Metzler Isoflavones modulate the glucuronidation of estradiol in human liver microsomes Carcinogenesis 26 2005 2172 2178
35. Y. Liu, J. Ramirez, L. House, and M.J. Ratain The UGT1A128 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation Eur. J. Cancer 46 2010 2097 2103
36. J. Zhou, T.S. Tracy, and R.P. Remmel Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP- glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites Drug Metab. Dispos. 38 2010 431 440
37. V. Uchaipichat, A. Galetin, J.B. Houston, P.I. Mackenzie, J.A. Williams, and J.O. Miners Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites Mol. Pharmacol. 74 2008 1152 1162
38. F.L. Sauvage, J.M. Gaulier, G. Lachatre, and P. Marquet Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis Clin. Chem. 54 2008 1519 1527
39. V.C. Peterkin, J.N. Bauman, T.C. Goosen, L. Menning, M.Z. Man, J.D. Paulauskis, J.A. Williams, and S.P. Myrand Limited influence of UGT1A128 and no effect of UGT2B72 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes Br. J. Clin. Pharmacol. 64 2007 458 468
40. Y. Duguay, C. Baar, F. Skorpen, and C. Guillemette A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity Clin. Pharmacol. Ther. 75 2004 223 233
41. N. Djebli, N. Picard, J.P. Rerolle, Y. Le Meur, and P. Marquet Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients Pharmacogenet. Genomics 17 2007 321 330